ZVSA ZyVersa Therapeutics
- 4.2536
- -0.0564-1.31%
- 4.2500
- -0.0036-0.08%
ZyVersa Therapeutics News
Peering Into ZyVersa Therapeutics's Recent Short Interest
ZyVersa Therapeutics's (NYSE:ZVSA) short percent of float has fallen 96.61% since its last report. The company recently reported that it has 15 thousand shares sold short, which is 2.06% of all regula
ZyVersa Therapeutics (ZVSA.US): The 2024 Q1 financial report achieved revenue of $0, with a previous value of $0; earnings per share of -$4.53, previous value of -$135.88, and expected value of -$3.70.
ZyVersa Therapeutics (ZVSA.US): The 2024 Q1 financial report achieved revenue of $0, with a previous value of $0; earnings per share of -$4.53, previous value of -$135.88, and expected value of -$3.70.
ZyVersa Therapeutics Q1 2024 Adj EPS $(4.53) Misses $(3.70) Estimate
ZyVersa Therapeutics (NASDAQ:ZVSA) reported quarterly losses of $(4.53) per share which missed the analyst consensus estimate of $(3.70) by 22.43 percent.
ZyVersa Therapeutics 1Q Loss/Shr $4.53 >ZVSA
ZyVersa Therapeutics 1Q Loss/Shr $4.53 >ZVSA
10-Q: Quarterly report
Press Release: ZyVersa Therapeutics Reports First Quarter, 2024 Financial Results and Provides Business Update
ZyVersa Therapeutics Reports First Quarter, 2024 Financial Results and Provides Business Update Key Highlights: -- Second research site selected to enhance enrollment in the Phase 2a clinic
10-K/A: Annual report (Amendment)
ZyVersa Therapeutics' CEO, Stephen C. Glover, to Participate in the 2024 BIO International Convention
ZyVersa is advancing a dynamic pipeline of drug candidates with multiple programs built around two proprietary technologies – Cholesterol Efflux Mediator VAR 200 for treatment of kidney diseases, and Inflammasome
Why Clever Leaves Holdings Shares Are Trading Lower By Around 60%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Shares of Clever Leaves Holdings Inc. (NASDAQ:CLVR) fell sharply during Monday's session after the company announced that it will voluntarily delist its common shares from the Nasdaq and deregister it
What's Going On With ZyVersa Stock?
ZyVersa Therapeutics, Inc. (NASDAQ:ZVSA) shares are trading higher Monday after the company announced the publication of a scientific paper in a peer-reviewed journal that reinforces the rationale for
ZyVersa Therapeutics Stock Jumps 8%
ZyVersa Therapeutics Shares Resume Trade Following Circuit Breaker Halt
ZyVersa Therapeutics Shares Resume Trade Following Circuit Breaker Halt
ImmunityBio, Aquestive Therapeutics, Clever Leaves Holdings Among Healthcare Movers
ZyVersa Therapeutics Announces Publication Reinforcing the Rationale for Inhibiting ASC With IC 100 to Potentially Attenuate Cardiac Comorbidities in Patients With Alzheimer's Disease
This publication, authored by leading experts in inflammasome-mediated inflammation and neurology at University of Miami Miller School of Medicine, demonstrates that multiple inflammasome triggers (NLRP1 and pyrin)
Why Aon Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Shares of Aon plc (NYSE:AON) fell sharply during Friday's session after the company reported worse-than-expected quarterly financial results.Aon posted adjusted earnings of $5.66 per share, missing ma
PEGY, CGEM and IFBD Among Mid-day Movers
ZyVersa Therapeutics To Carry Out 1-for-10 Reverse Stock Split On April 26th, 2024
April 25th - $ZyVersa Therapeutics(ZVSA.US)$ is about to implement a 1-for-10 reverse stock split of shares. The shares will begin trading on a split-adjusted basis from April 26th, 2024.$ZyVersa Ther
ZyVersa Therapeutics Approves Reverse Stock Split
ZyVersa Therapeutics Price Target Maintained With a $12.00/Share by HC Wainwright & Co.
ZyVersa Therapeutics Price Target Maintained With a $12.00/Share by HC Wainwright & Co.
Buy Rating Affirmed: ZyVersa Therapeutics' Promising Pipeline and Strategic Advancements
Analysis
Price Target
No Data
